The pharmaceutical executives weren't chasing headlines in 2014 when they boxed up samples of pembrolizumab and launched them toward the International Space Station. They were chasing something more prosaic: better crystals. Strange as it sounds, growing drug crystals in the absence of gravity can yield surprisingly uniform structures—the kind that make formulation chemists quietly excited.
Over eight years and multiple missions, Merck's gambit paid off. The microgravity environment delivered more homodisperse crystalline suspensions, improvements NASA later documented as contributing to refinements in the FDA-approved cancer therapy now marketed as Keytruda. NASA published a case note on January 6, 2026, tying ISS work to FDA-approved therapy formulation improvements, and suddenly what had been a scientific curiosity—could drugs behave differently up there?—became a manufacturing question. And wherever manufacturing questions arise, money tends to follow.
Fast forward to May 2026. Varda Space Industries announced a partnership with United Therapeutics on May 13 to process medicines in orbit using free-flying capsules that return samples to Earth. A month earlier, Redwire had spun out SpaceMD, a pharmaceutical-focused subsidiary built around its PIL-BOX crystallization platform, carrying samples from Eli Lilly, Bristol Myers Squibb, and various academic labs on repeat missions. LambdaVision closed a $7 million seed round in November 2025 to scale production of an artificial retina—in space.
These aren't blue-sky NASA experiments anymore. They're commercial services with price tags and service-level agreements, targeting an industry that spends billions hunting for formulation advantages and faster routes to market.
The Landscape Taking Shape
The global space economy reached $626.4 billion in 2025, according to Novaspace projections, and is tracking toward roughly $1 trillion by 2034. Microgravity drug development occupies a small but increasingly professionalized corner of that expansion. The ISS National Lab sponsored over 100 payloads in 2024 alone, with pharmaceutical crystallization and 3D bioprinting featured prominently. Crew time remains scarce and sample-return windows constrain iteration cycles, but the pace is picking up.
Redwire returned its fourth batch of pharmaceutical crystals in February 2025. Aspera Biomedicines launched its second ADAR1p150 crystallization mission in May 2026, targeting an oral formulation for rebecsinib, an ADAR1 inhibitor moving through clinical development. These missions follow a pattern: send samples up, bring crystals down, characterize the results, repeat.
The technical logic is straightforward, even elegant. Microgravity suppresses the buoyancy-driven convection and sedimentation that govern crystal growth on Earth. Mass transport changes. Self-assembly proceeds differently. Reviews published in early 2025 and NASA materials from April 2023 documented consistent gains in protein crystallization quality. Larger, more ordered crystals can improve drug stability and solubility—which translates, sometimes, to better delivery vehicles. For an industry perpetually chasing superior polymorphs or trying to convert intravenous therapies into subcutaneous injections, the promise is concrete.
But promise doesn't build an industry. Infrastructure does. And that's what's changing.
Redwire's PIL-BOX platform has been validated across multiple return missions between 2023 and 2026, supporting multi-partner campaigns. Lilly reported improved insulin crystal uniformity after ISS runs. SpacePharma's miniaturized DIDO and μLab systems have flown multiple missions, including collaborations with Roche-linked SPANCER 3D tissues for cancer diagnostics and drug testing. Space Tango's automated bioreactors support drug-delivery device printing under NASA's InSPA program, with hardware demonstrations as recently as late March 2026.
Three Forces Converging
The shift from proof-of-concept to production pilot appears driven by three interlocking developments.
First: reentry logistics have been solved. Varda's W-1 mission became the first FAA-licensed commercial reentry under Part 450 regulations in February 2024, establishing a repeatable capsule-return model. That regulatory milestone matters more than it might seem. It unlocked free-flying manufacturing—no waiting for ISS crew schedules or competing for cargo slots. Varda's subsequent deal with United Therapeutics follows that playbook: process small molecules in orbit, bring them home on your own timeline. Michael Reilly, Varda's chief science officer, described microgravity processing in May 2026 interviews as a pathway to novel formulations for chronic disease therapies. The framing was careful, but the implication was clear: this could become routine.
Second: platform standardization is accelerating. Exobiosphere, a Luxembourg-based startup, raised €2 million in seed funding in April 2025 and received $1 million through "Meet the Drapers" by March 31, 2026. The company bills itself as the first contract research organization dedicated to high-throughput testing in microgravity—a niche category, to be sure, but one with a certain logic.
Its Orbital High-Throughput Screener system claims capacity for over 2,000 parallel assays per mission. The platform validated automated nanoliter dispensing into 384- and 1,536-well plates during a parabolic flight in June 2025. CEO Kyle Acierno, announcing a partnership with Voyager Technologies in May 2026, emphasized demand for "automation, higher cadence, and permanent hardware to unlock pharma scale." Exobiosphere has secured an ESA utilization contract to design and operate the system on Vast's Haven-1 station, with milestones extending into 2027, and signed a mission-management agreement with Voyager for ISS integration.
Redwire has pursued a similar strategy. Its BioFabrication Facility printed what it described as the first live human heart tissue in orbit, announced in May 2024, followed by knee meniscus and liver constructs through 2025. These aren't one-off demonstrations; they're repeat services with paying customers. Purdue University partnered with Redwire in November 2025 on crystallization systems engineering, blending academic research with commercial execution.
Third: the biology itself is evolving. Organoids and 3D cell cultures—already central to drug discovery on Earth—behave differently when buoyancy vanishes. A December 2024 review and earlier work in Scientific Reports documented altered proliferation, differentiation, and drug sensitivity in colorectal organoids under simulated microgravity. Pluripotent stem cells exhibit modified self-renewal patterns; cardiomyocytes show maturation effects. A January 2026 review in Nature Reviews Drug Discovery highlighted the translational potential of organoid and organ-on-chip models, increasingly integrated with AI and automation platforms. Microgravity introduces another variable—one that might reveal disease mechanisms or compound responses invisible in standard culture.
Cases in Point
Merck's Keytruda program remains the canonical example, the one everyone cites. Published in npj Microgravity in 2019 and updated through NASA case materials into 2026, the research demonstrated that microgravity-grown pembrolizumab crystals yielded more uniform suspensions, which ultimately fed into formulation improvements linked to FDA approval. Eight years and multiple ISS flights. It took time, but the investment penciled out.
Lilly's insulin crystallization experiments, conducted via Redwire's PIL-BOX and returned in 2024, reported similar gains: improved crystal uniformity that could streamline manufacturing or enable new delivery mechanisms. Aspera Biomedicines is making the same bet. Its ADAR1p150 crystallization flights—the second launched aboard SpaceX CRS-34 in May 2026—aim to support development of an oral formulation for rebecsinib. Aspera is now on its 11th ISS mission, funded under NASA's InSPA program, using PIL-BOX hardware. The company hasn't disclosed cost structures, but the repetition suggests they're seeing value.
LambdaVision represents a different model entirely: using microgravity not to characterize molecules but to manufacture them. The company's layer-by-layer protein thin-film process, validated over nine ISS missions, produces an artificial retina for treating retinitis pigmentosa. The $7 million seed round announced in November 2025 funds scale-up efforts, and a memorandum of understanding signed with Vast in late June 2026 signals plans to extend production to Haven-1 and future commercial stations.
Then there's the reentry approach. Varda's arrangement with United Therapeutics, announced May 13, 2026, centers on small-molecule optimization in free-flying capsules. Process the drug candidate in orbit for weeks or months, refine crystal structure or particle size distribution, then return samples to Earth for characterization. No crew required, no ISS logistics queue. It's a wager that microgravity processing can become just another step in the development workflow rather than an exotic research detour.
The 2027–2030 Platform Question
The ISS is scheduled for retirement around 2030, and NASA is working to ensure continuity of low Earth orbit research access. A Government Accountability Office report from May–June 2026 flagged decisions needed to avoid a gap. Commercial stations are the proposed solution, but timelines keep drifting.
Vast's Haven-1 initially targeted mid-2026; as of January 2026 interviews, the launch window had shifted to early 2027. Axiom Station's first module carries a no-earlier-than date in 2027. Starlab, the Voyager Space and Airbus joint venture, passed its NASA Commercial Critical Design Review in February 2026 but isn't expected to launch until 2029, according to April 2026 SEC filings.
For pharmaceutical companies contemplating orbital work, this introduces platform risk. ISS capacity is finite—those 100-plus payloads in 2024 covered all scientific disciplines—and the commercial alternatives are still being built. Exobiosphere's Acierno has called publicly for "permanent hardware" in orbit to meet pharmaceutical R&D cadence requirements. Varda's free-flyer model sidesteps the station bottleneck entirely, trading crew oversight for autonomous systems. SpacePharma's miniaturized labs and yuri's modular bioreactors represent middle paths: automated platforms that can operate on ISS today and theoretically migrate to commercial stations when they come online.
The regulatory framework remains unsettled. The FDA has issued no microgravity-specific current Good Manufacturing Practice guidelines; sponsors must navigate existing quality frameworks, most recently updated through March 2026. That means chain-of-custody documentation, environmental controls, and validation plans adapted to orbital conditions. No one has yet submitted a microgravity-manufactured drug for regulatory approval, but when someone does, the agency will expect terrestrial-level rigor. Industry observers at the 2025 American Society for Gravitational and Space Research annual meeting have suggested that harmonization efforts—qualification of microgravity environments, in-process controls, validation packages—will likely emerge within existing cGMP and chemistry-manufacturing-controls frameworks rather than as wholly new guidance.
Where the Bet Lies
The question has shifted. It's no longer whether microgravity can improve drug molecules—the Keytruda case and subsequent work have established plausibility. The question now is whether it can do so cheaply and reliably enough to justify routine integration into pharmaceutical development pipelines.
Acierno's positioning of the OHTS platform as "standardized, repeatable microgravity screening" and Varda's capsule-return logistics signal a deliberate move away from boutique research toward industrial service. Redwire's SpaceMD subsidiary, launched in August 2025, exists explicitly to commercialize what was once a NASA showcase.
But adoption hinges on demonstrable return on investment, and pharma executives are famously unsentimental about R&D spending. They'll pay for microgravity runs if the work accelerates hit-to-lead timelines, enables subcutaneous formulations of intravenous drugs, or unlocks polymorphs that ease manufacturing bottlenecks. They won't pay for marginal gains or results that can't be reproduced batch to batch. The 2,000-assay capacity Exobiosphere promises, the repeat PIL-BOX batches Redwire delivers, the capsule flights United Therapeutics is funding—these represent attempts to cross the threshold from "interesting science" to "useful tool."
Platform availability remains the gating factor. Haven-1's early-2027 target, Axiom's post-2027 schedule, and Starlab's 2029 projection suggest a multi-year window during which ISS capacity and nascent commercial platforms will coexist, probably awkwardly. Companies securing payload slots now—Exobiosphere's ESA utilization contract, LambdaVision's Vast memorandum, Aspera's repeat ISS missions—are positioning for first-mover advantage when launch cadence improves and station capacity expands.
The broader space economy's trajectory toward $1 trillion by 2034 doesn't guarantee microgravity pharma will capture a meaningful slice. What it does indicate is capital flowing into orbital infrastructure—launch vehicles, reentry systems, station modules, automation platforms—that makes routine microgravity work at least plausible. If another Keytruda-scale success emerges in the 2027–2030 window, the industry will pay close attention.
Until then, drug development in orbit remains a high-stakes wager: scientifically validated, commercially nascent, and utterly dependent on whether the promised platforms show up on schedule. Which, in the space business, is never a sure thing.
